Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Nagare, Rohit Pravina | Sneha, Smarakana | Sidhanth, Chirukandatha | Roopa, S.b | Murhekar, Kanchanc | Shirley, Sundersinghc | Swaminathan, Rajaramand | Sridevi, Velusamye | Ganesan, Trivadi Sundarama; b; *
Affiliations: [a] Laboratory for Cancer Biology, Department of Medical Oncology and Clinical research, Cancer Institute (WIA), Chennai, Tamilnadu, India | [b] Department of Medical Oncology and Clinical Research, Cancer Institute (WIA), Chennai, Tamilnadu, India | [c] Department of Pathology, Cancer Institute (WIA), Chennai, Tamilnadu, India | [d] Division of Epidemiology and Cancer Registry, Cancer Institute (WIA), Chennai, Tamilnadu, India | [e] Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamilnadu, India
Correspondence: [*] Corresponding author: Trivadi Sundaram Ganesan, Department of Medical Oncology and Clinical Research, Cancer Institute (WIA), Chennai, Tamilnadu, India. Tel.: +91 44 22209150; Fax: +91 44 24912055; E-mail: [email protected]@cancerinstitutewia.org.
Abstract: BACKGROUND: There has been variability between laboratories in the identification of cancer stem cells (CSCs) markers for epithelial ovarian cancer (EOC). We have evaluated three new surface markers for EOC to identify CSCs precisely. METHODS: Three new putative CSCs specific surface markers CD9, CD24 and EPHA1 identified by a bioinformatics approach were evaluated in normal ovary, fallopian tube and ovarian tumours. RESULTS: The expression of CD9 alone was observed in normal ovarian surface epithelium and fallopian tube whereas CD24 and EPHA1 were not expressed (n= 5). CD24 was expressed in all tumours (N= 101) while CD9 and EPHA1 were expressed in 89 and 71 tumours, respectively. The statistical analysis showed significant correlation of the stage of the disease (p< 0.0001), type of surgery (p< 0.0001) and residual disease (p< 0.0001) with overall survival. Although expression of CD9, CD24 and EPHA1 was observed in the majority of tumours there was no significant correlation with outcome. In patients who underwent primary surgery, increased expression of CD24 significantly correlated with poor survival. The expression of CD24 was significantly reduced (p< 0.002) upon analysis of paired sections from patients prior to surgery and at interval debulking surgery (n= 16). CONCLUSION: These findings suggest that overexpression of these new markers may be useful in identifying and targeting ovarian CSCs and CD24 may be a putative CSCs marker in ovarian cancer.
Keywords: Ovarian cancer stem cells, serous ovarian cancer, CD24, CD9, EPHA1, primary surgery, interval debulking surgery, clinical outcome
DOI: 10.3233/CBM-201463
Journal: Cancer Biomarkers, vol. 28, no. 3, pp. 397-408, 2020
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]